HK Stock Market Move | HBM HOLDINGS-B(02142) rose more than 7% during trading hours, achieving record high annual revenue and profits. The company has officially entered the 3.0 strategic phase.

HBM HOLDINGS-B(02142) rose more than 7% during trading, rising 4.96% as of the time of publication to 13.13 Hong Kong dollars, with a trading volume of 56.8377 million Hong Kong dollars. On the news front, Hepion Pharmaceuticals announced its annual results, with the company achieving total revenue of approximately 1.1 billion yuan, a year-on-year increase of 314.6%; a profit of approximately 648 million yuan, a year-on-year increase of 33 times, both reaching historical highs; and cash and cash equivalents of approximately 2.833 billion yuan, an increase of 141.6% compared to the end of the previous year. The company stated that the core driver of the performance growth comes from revenue growth brought by strategic partnerships and global licensing agreements, as well as continuous improvement in operational efficiency. Hepion Pharmaceuticals' founder, chairman, and CEO Wang Jinsong said, "2025 is a crucial year in the development of Hepion Pharmaceuticals, as the company officially enters the 3.0 strategic phase and establishes a development blueprint to become a leading global platform-based biopharmaceutical group by 2028." Currently, the company's strategy is driven by three major business growth engines, including leveraging Hepion's unique antibody technology platform to build an artificial intelligence-driven antibody drug R&D "new infrastructure"; collaborating with multinational pharmaceutical companies to promote long-term strategic cooperation based on technology platforms; and maximizing global value in the company's own areas of late-stage pipeline in autoimmune diseases, tumors, and other fields through Hepion Pharma.